$2.54T
Total marketcap
$184.34B
Total volume
BTC 50.10%     ETH 15.86%
Dominance

CRISPR Therapeutics AG CRSP Stock

71.47 USD {{ price }} -2.028781% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
5.74B USD
LOW - HIGH [24H]
71.24 - 73.71 USD
VOLUME [24H]
1.21M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-1.94 USD

CRISPR Therapeutics AG Price Chart

CRISPR Therapeutics AG CRSP Financial and Trading Overview

CRISPR Therapeutics AG stock price 71.47 USD
Previous Close 58.96 USD
Open 58.6 USD
Bid 0 USD x 800
Ask 0 USD x 900
Day's Range 58.1 - 59.47 USD
52 Week Range 38.94 - 86.95 USD
Volume 953.09K USD
Avg. Volume 1.37M USD
Market Cap 4.65B USD
Beta (5Y Monthly) 1.658098
PE Ratio (TTM) N/A
EPS (TTM) -1.94 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 84.12 USD

CRSP Valuation Measures

Enterprise Value 3.01B USD
Trailing P/E N/A
Forward P/E -8.930303
PEG Ratio (5 yr expected) 0.05
Price/Sales (ttm) 46.404625
Price/Book (mrq) 2.5059524
Enterprise Value/Revenue 30.034
Enterprise Value/EBITDA -5.592

Trading Information

CRISPR Therapeutics AG Stock Price History

Beta (5Y Monthly) 1.658098
52-Week Change -15.79%
S&P500 52-Week Change 20.43%
52 Week High 86.95 USD
52 Week Low 38.94 USD
50-Day Moving Average 57.24 USD
200-Day Moving Average 54.18 USD

CRSP Share Statistics

Avg. Volume (3 month) 1.37M USD
Avg. Daily Volume (10-Days) 1.47M USD
Shares Outstanding 78.94M
Float 77.94M
Short Ratio 7.85
% Held by Insiders 1.48%
% Held by Institutions 67.98%
Shares Short 12.19M
Short % of Float 15.65%
Short % of Shares Outstanding 15.44%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -560.23%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -14.47%
Return on Equity (ttm) -25.56%

Income Statement

Revenue (ttm) 100.26M USD
Revenue Per Share (ttm) 1.28 USD
Quarterly Revenue Growth (yoy) 10538.29%
Gross Profit (ttm) -570697000 USD
EBITDA -538492032 USD
Net Income Avi to Common (ttm) -524023008 USD
Diluted EPS (ttm) -6.6
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 1.88B USD
Total Cash Per Share (mrq) 23.86 USD
Total Debt (mrq) 240.27M USD
Total Debt/Equity (mrq) 12.95 USD
Current Ratio (mrq) 12.998
Book Value Per Share (mrq) 23.52

Cash Flow Statement

Operating Cash Flow (ttm) -351703008 USD
Levered Free Cash Flow (ttm) -216668496 USD

Profile of CRISPR Therapeutics AG

Country United States
State N/A
City Zug
Address Baarerstrasse 14
ZIP 6300
Phone 41 41 561 32 77
Website https://www.crisprtx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 458

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Q&A For CRISPR Therapeutics AG Stock

What is a current CRSP stock price?

CRISPR Therapeutics AG CRSP stock price today per share is 71.47 USD.

How to purchase CRISPR Therapeutics AG stock?

You can buy CRSP shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for CRISPR Therapeutics AG?

The stock symbol or ticker of CRISPR Therapeutics AG is CRSP.

Which industry does the CRISPR Therapeutics AG company belong to?

The CRISPR Therapeutics AG industry is Biotechnology.

How many shares does CRISPR Therapeutics AG have in circulation?

The max supply of CRISPR Therapeutics AG shares is 80.28M.

What is CRISPR Therapeutics AG Price to Earnings Ratio (PE Ratio)?

CRISPR Therapeutics AG PE Ratio is now.

What was CRISPR Therapeutics AG earnings per share over the trailing 12 months (TTM)?

CRISPR Therapeutics AG EPS is -1.94 USD over the trailing 12 months.

Which sector does the CRISPR Therapeutics AG company belong to?

The CRISPR Therapeutics AG sector is Healthcare.

CRISPR Therapeutics AG CRSP included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NASDAQ Global Market Composite NQGM 2185.85 USD
-0.31
2177.48 USD 2204.21 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD